Subscribe
Menu
Login
Search
Login
News & Opinion
Publications
AN INTERACTIVE EXPERIENCE
Current Issue
May 2022, Issue 2
Preview This Issue
Archives
Features
Quarterly Magazine
Current Issue
Spring 2022
Preview This Issue
Archives
Features
Categories
Biochemistry
Cancer
Cell Biology
Community
Drug Development
Environment
Evolution
Genetics
Immunology
Microbiology
Neuroscience
Physiology
Public Health
Zoology
Multimedia
Crossword Puzzles
Infographics
Science Snapshot
Videos
Webinars
Research Resources
Podcasts
Events
Infographics
eBooks
Videos
The Scientist University
Research Products Blog
Articles
Subscribe
Home
Subjects
car-t
car-t
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 22, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Novartis Drops Gene Therapy Research
Ben Andrew Henry | Sep 6, 2016
The company has shuttered its experimental cell and gene cancer therapy unit, firing more than 100 researchers.
Streamlining CAR T Cell Workflows with Automation
The Scientist Creative Services Team in collaboration with Thermo Fisher Scientific | Sep 7, 2021
Automated counterflow centrifugation systems accelerate cell therapy workflow processes while maintaining cell yields and efficacy.
Cancer Immunotherapy Trial Suspended After Deaths
Kerry Grens | Jul 8, 2016
Juno Therapeutics asks the US Food and Drug Administration for permission to restart the CAR-T experiments without chemotherapy.
TS Picks: March 16, 2016
Kerry Grens | Mar 16, 2016
Corrections give belated credit for immunotherapy; mosquitoes have been bugging us long before Zika; the bright side of irreproducibility